ACM
NVCR icon

Asymmetry Capital Management’s NovoCure NVCR Stock Holding History

Asymmetry Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-157,176
Closed -$1.34M – 24
2016
Q3 		$1.34M Buy
+157,176
New +$1.43M 2.33% 15

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Asymmetry Capital Management's NVCR Position: Q4 2016 in Review

Asymmetry Capital Management sold out of NovoCure (NVCR) in Q4 2016, closing a stake of 157,176 shares — an estimated $1.34M sold.

Asymmetry Capital Management first reported a position in NVCR in Q3 2016 and held it in 1 quarter. The position peaked at $1.34M in Q3 2016. 78 funds tracked by Wall St. Rank hold NVCR as of Q4 2016.

  • Asymmetry Capital Management reported no remaining NovoCure position as of Q4 2016 after selling out during the quarter.
  • Asymmetry Capital Management sold 157,176 NovoCure shares in Q4 2016, an estimated $1.34M.
  • Asymmetry Capital Management first reported a position in NovoCure in Q3 2016 and held it in 1 quarter.
  • Asymmetry Capital Management's NovoCure position peaked at $1.34M in Q3 2016.
  • 78 funds tracked by Wall St. Rank held NovoCure as of Q4 2016.

Based on Asymmetry Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.